-+ 0.00%
-+ 0.00%
-+ 0.00%

Allarity Expands Phase 2 Stenoparib Trial to Three Ovarian Cancer Patient Cohorts

PUBT·11/16/2026 12:50:37
Listen to the news
Allarity Expands Phase 2 Stenoparib Trial to Three Ovarian Cancer Patient Cohorts
  • Allarity Therapeutics today expanded its Phase 2 stenoparib trial in advanced ovarian cancer to three patient cohorts.
  • Newly eligible patients include those with primary platinum-refractory disease or clinically evaluable disease that cannot be measured under standard criteria.
  • The cohorts will be evaluated independently, with a strong result in any group potentially supporting further development.
  • Earlier findings presented at the ESMO Gynaecological Cancers Congress in June 2026 showed durable clinical benefit, including a confirmed complete response.
  • Additional clinical and scientific data will be released at future scientific and clinical conferences.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allarity Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611160750PRIMZONEFULLFEED1001303826) on November 16, 2026, and is solely responsible for the information contained therein.